# PRESS RELEASE 2012

## Ferring’s European Marketing Authorisation Application for controlled release misoprostol vaginal delivery system for the induction of labour accepted for review

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 05 November 2012

Ferring Pharmaceuticals announced today that it has received confirmation from European health authorities that the Marketing Authorisation…

## Ferring Announces FDA Acceptance of NDA Filing for Controlled Release Misoprostol Vaginal Insert for Decreasing Time to Vaginal Delivery in Women

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 23 October 2012

Ferring Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA)…

## New study showed desmopressin melt reduced sleep disruption in bedwetting children

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 12 October 2012

Preliminary results from a new, prospective study presented today at the first Joint Congress of the International Children’s Continence…

## Fonds de solidarité FTQ, CTI Life Sciences Fund and Ferring Pharmaceuticals Create a New Biotech in Québec

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 05 October 2012

The Fonds de solidarité FTQ (the “Fonds”), CTI Life Sciences Fund and Ferring Pharmaceuticals are pleased to announce…

## FDA approves Ferring’s PREPOPIK™ (sodium picosulfate, magnesium oxide, and anhydrous citric acid) for colonoscopy prep

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 17 July 2012

The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market PREPOPIK (sodium picosulfate, magnesium…

## Ferring Pharmaceuticals Acquires Licensing Rights for Elobixibat from Albireo AB

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 03 July 2012

Ferring Pharmaceuticals (Ferring) and Albireo AB (Albireo) announced today that they have signed a license agreement under which Ferring has…

## Ferring Pharmaceuticals donates $10 million to the Salk Institute for Biological Studies

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 07 June 2012

Ferring Pharmaceuticals, a global, specialty biopharmaceuticals company, has donated $10 million to support research at the Salk Institute…

## New data show that FIRMAGON® (degarelix) is non-inferior to the combination of goserelin plus bicalutamide at reducing prostate volume in patients with advanced hormone-dependent prostate cancer while offering better relief from lower urinary tract symptoms

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 28 February 2012

Two new studies presented at the 27th Annual European Association of Urology (EAU) Congress reported that…

## Ferring announces new million euro educational initiative with International Federation of Fertility Societies (IFFS) and Elsevier

By [pulse](/content/author/pulse/index.html) in [PRESS RELEASE 2012](/content/category/press-release-2012/index.html) on 08 February 2012

World leader in fertility treatments, Ferring Pharmaceuticals, announced today at the 2012 Updates in Infertility Treatment (UIT) meeting that…